Novamind (NM) began a Phase II trial on psilocybin for depression, which is sponsored by the non-profit Usona Institute.
Numinus (NUMI) received Health Canada approval to research the plants that are used to make ayahuasca and a mescaline-containing cactus called San Pedro.
VANCOUVER, BC, CANADA (March 3, 2022) – LOVE Pharma Co. (“LOVE” and or “The Company”)(CSE: LUV) (FSE: G1Q0), the Company is pleased to announce updated details on the proposed Microdoz Therapy acquisition (originally announced in a press release on November 23, 2021), whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University, the top psychedelic center in the World, located in the eastern United States, to conduct a landmark study into the potential of psilocybin assisted treatment of cannabis use disorder. The company looks forward to working with the university and research experts on the study and, ultimately, licensing and commercializing the intellectual property developed by the landmark study.
“This is a significant opportunity to develop treatments with efficacy for people who are today subject to Cannabis Use Disorder and those who will become subject to it in the future,” said Mr. Zach Stadnyk, Love Pharma CEO. “The U.S. cannabis industry is forecast to surpass $41 billion by 20252, and the National Institute on Drug Abuse has released research suggesting 9% – 30% of people using cannabis may develop cannabis use disorder3, so we see an opportunity where Love can help people facing this disorder along with our research partners, while at the same time developing a lucrative market for treatment that will benefit our shareholders.”
Lucas Corrubia, Co-founder of Microdoz and PhD Candidate, stated: “the Hopkins team has paved the way for clinical psychedelic therapy research, and we are optimistic in working with their successful research team to develop a new therapy for cannabis abuse, and develop a long-lasting relationship with the global leader in medical research sciences”.
Through the planned acquisition of Microdoz, partnering with the university to conduct this comprehensive study relating to the potential of psilocybin assisted treatment for cannabis use disorder will help to establish consumer confidence and guide the development and use of psilocybin product development and application. As a result, LOVE will continue to develop innovative products that establish new consumer applications. Science and efficacy are paramount to the LOVE Pharma strategy, as indicated by the Company’s research initiative to take place at Johns Hopkins. We look forward to completing this clinical study and licensing the intellectual property produced from it and, eventually, commercializing the prospective findings furthering our footprint in the bourgeoning psychedelics for therapeutic use space going forward and delivering value for our shareholders.
Terms of the Deal:
This acquisition is subject to final due diligence, and it is anticipated to close in the coming weeks, for which, there is no guarantee.
In addition, pursuant to the company’s stock option plan, the company has issued 3,000,000 inventive stock options to consultants of the issuer exercisable at a price of $0.05 per share for a period of five (5) years, vesting immediately.
Zachary Stadnyk, CEO and Director
About Love Pharma Inc.
With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
For further information, please contact:
Investor Relations
Telephone: 1 (604) 343-2977
E-mail: investors@love-pharma.com
www.love-pharma.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
VANCOUVER, BC / ACCESSWIRE / March 3, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today a strategic partnership with BioScript Solutions, a Canadian leader in specialty care. Under the terms of the partnership, NeonMind and BioScript Solutions will leverage BioScript Solutions’ extensive national network of community-based infusion clinics to expand access to NeonMind’s interventional psychiatry and unique treatment programs for Canadians.
Since 2001, BioScript Solutions’ clinical network has been providing patients with a safe, comfortable environment to receive specialty therapies for chronic health conditions. With over 100 conveniently located clinics across the country, run by a team of highly experienced nurses, BioScript remains committed to being at the forefront of innovative patient care. NeonMind expects to select and announce its first location within BioScript Solutions’ network in the first half of 2022. The Company expects to provide care through additional clinic locations throughout 2022, expanding to further locations and services in 2023 and beyond.
“We are thrilled to advance the development of our specialty clinics division through our partnership with BioScript Solutions,” said Robert Tessarolo, President & CEO of NeonMind. “We now have multiple strategic partnerships in place with leading specialty care providers and have built an enhanced clinic network with greater reach. This positions us well to identify and open high-impact clinic locations that will serve local community needs and expedite our time to market. We look forward to working with BioScript Solutions to bring the therapeutic benefits of interventional psychiatry including evidence-based innovative therapies such as psychedelic modalities to mental health patients across the nation.”
Commenting on the partnership, Chris Dalseg, Vice-President Strategic Growth and Marketing of BioScript Solutions, said, “This partnership with NeonMind is part of our ongoing mission to simplify access to specialty care for Canadians from coast to coast, and directly within their own communities. Mental health continues to be a growing global health concern, and we are thrilled to be able to continue expanding the breadth of our services supporting NeonMind’s novel approach to mental health treatments.”
About BioScript Solutions®
For over 20 years, BioScript Solutions has been committed to helping people with chronic illnesses achieve the best possible health outcomes. With our total care approach, we simplify access to complex drug therapies and deliver full-service specialty care solutions at every stage of the patients’ treatment journey. Through our logistics and distribution operations, specialty pharmacies, patient support programs and clinical services, BioScript Solutions® has the capability to manage the needs of manufacturers, payors, prescribers, and health care practitioners across Canada ― today, and tomorrow. To learn more, please visit www.bioscript.ca.
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.
NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-based innovative interventional psychiatry treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
SOURCE: NeonMind Biosciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/691372/NeonMind-and-BioScript-Solutions-Announce-Strategic-Partnership-Expanding-NeonMinds-Specialty-Clinic-Network-for-Interventional-Psychiatry-Treatments
Released March 3, 2022
Toronto, Ontario–(Newsfile Corp. – February 28, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation is pleased to announce its wholly owned subsidiary SR Wholesale in the Netherlands (“SR Wholesale“), has signed an exclusive distribution deal with Conor McGregor’s innovative sports recovery line, TIDL Sport.
Figure 1: SR Wholesale signs exclusive distribution deal with TIDL Sport – Conor McGregor’s innovative Sports Recovery line.
TIDL Sport products combine plant based therapy with exercise science and cryotherapy to assist active lifestyle enthusiasts. True sports recovery goes beyond temporary pain relief, and TIDL Sport products are scientifically curated with ingredients that target inflammation, the foundation of post exercise pain and soreness. The products have been clinically proven to reduce pain and aim to help consumers return to the activities that they love sooner, and pain free.
“I’ve been putting extra focus on my overall health for years now, which is why I’m so pleased that TIDL Sport is partnering with Red Light Holland. Our combined efforts to distribute products with the goal of education around sports recovery – both mentally and physically are where Red Light Holland and TIDL Sport are progressive and aligned.” said Conor McGregor.
TIDL Sport products are designed for the active lifestyle, no matter what the sport. Consumers range from weekend warriors to professional athletes, all whom recognize the importance of recovery and self care. The products focus on different segments of recovery, including relief with the current products and a pipeline that focuses on body recharge and nutrient replenishment.
“We are delighted to be partnering with Conor McGregor and The Anthos Group as Red Light Holland’s wholly-owned subsidiary SR Wholesale plans to be a big part of the distribution for Conor’s next generation sports recovery line – TIDL Sport,” said Todd Shapiro, CEO and Director of Red Light Holland. “The foundation of TIDL Sport and Conor McGregor are completely aligned with Red Light Holland. Together we believe in naturally occurring therapies, healthy and active lifestyles and living in the moment with the goal of long-term recovery while focusing on the betterment of physical and mental health. We see a large opportunity to educate around recovery and wellness and look forward to working closely with Conor and Badal Shah, Chief Executive Officer at The Anthos Group now and into the future.”
“One of Red Light Holland’s focus for 2022 is Mind to Toe wellness. Everyone at SR Wholesale is very excited to now have the access to distribute TIDL Sport, especially in the Netherlands and potentially across Europe – where Conor McGregor is beloved!” said Hans Derix, President of Red Light Holland.
Under the terms of the deal, Red Light Holland’s wholly-owned subsidiary SR Wholesale’s territory to distribute TIDL Sport, shall mean the country of The Netherlands and on a case by case basis, where no there is no conflict with an existing TIDL Sport Distributor, into all regions of Europe.
The brand’s flagship product, the TIDL Sport Plant-Powered Cryotherapy Topical Spray, delivers powerful relief through cryotherapy and novel plant science, delivering immediate pain relief and leaving athletes feeling refreshed as a part of the active lifestyle. The revolutionary topical spray has 360° spray technology for easy, full body self-application and promotes long term healing by addressing pain and inflammation directly at the source. The plant based ingredients in TIDL Sport range from plant derived extracts to well known anti-inflammatory agents that are all organic in nature. The enhanced touch-free formula sprays on clean with an immediate cooling relief, which increases blood flow to the site of application and enables the plant based ingredients to self absorb and go to work.
In addition, the Company’s board of directors approved the grant of 6,600,000 options and awarded 850,000 restricted stock units to certain directors, officers, and consultants of the Company. Each option will entitle the holder thereof to acquire one common share in the capital of Company for a period of three years from the date of issuance, which is expected to on or before March 7, 2022, at an exercise price equal to the greater of (i) $0.12, and (ii) the Company’s closing price on the Canadian Securities Exchange on the day prior to issuance, and subject to the terms and conditions of the Company’s stock option plan. The options will vest quarterly at the end of each fiscal quarter of the Company’s 2023 fiscal year. The options granted to directors of the Company are compensation for their services over the fiscal year ending March 31, 2023. All options and restricted stock units awards will be subject to a hold period of four months plus one day from the date of issuance.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: Todd@RedLight.co
Website: www.RedLight.co
About TIDL Sport
TIDL Sport infuses plant powered therapy with fitness and nutrition science to meet the needs of athletes to perform at the highest level. The flagship product is a plant-powered cryotherapy topical spray that has 360° spray technology for easy, full body self-application. TIDL Sport products are available in select national retailers in the U.S., globally in over 25 countries, and on the company website: www.tidlsport.com
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to: statements with respect to the Company’s plans for its wholly-owned subsidiary SR Wholesale to be a big part of the distribution for Conor’s next generation sports recovery line – TIDL Sport, the Company’s plans to work with Conor and Badal Shah in the future, and statements with respect to the Company’s business focus in 2022.
Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the COVID-19 pandemic impact on the Canadian economy and Red Light Holland’s business, the Company’s ability to carry out its plans with respect to SR Wholesale distributing Conor’s products, the willingness and ability of Conor and Badal Shah to continue working with SR Wholesale and the Company, no change to laws or regulations that negatively affect Red Light Holland’s business; there will be a demand for Red Light Holland’s products in the future; no unanticipated expenses or costs arise. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to continue as a going concern; the inability of the Company to obtain all necessary governmental and/or other regulatory approvals, licenses, and permits necessary to operate and expand the Company’s facilities; the effect of regulatory and/or political change and its effect on the legislation and regulations surrounding the psychedelics industry; negative perception of the medical-use and adult-use psilocybin industry; the potential unviability of psilocybin for medical and/or scientific purposes; the inability of the Company to continue its growth; the Company’s limited operating history; reliance on management; the Company’s requirements for additional financing; and competition for mental health and wellness investments.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics
VANCOUVER, BC, Feb. 24, 2022 – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) (FSE: 31R) (“Revive”) for use in clinical research studies. The Company previously signed a supply agreement with Revive in October, 2021.
In fulfilling of the purchase order, HAVN Life will export naturally derived GMP psilocybin extract from its facility in Jamaica into the U.S. through its distribution partner, Mycrodose Therapeutics Inc. (“Mycrodose”) for use by the University of Wisconsin-Madison (“UW-Madison”), a Contract Research Organization (“CRO”) for Revive. This shipment of naturally derived psilocybin will allow UW-Madison to conduct research and formulation work to finalize dosing and delivery mechanisms in support of the various studies to be sponsored by Revive using an oral-thin and Hydra-gel delivery systems of psychedelics to treat mental health disorders.
“We are so pleased to be able to supply our naturally derived, GMP psilocybin for this potentially ground-breaking research related to addiction disorders,” says HAVN Life CEO Tim Moore. “It is our hope that research like this will help in the push toward the rescheduling of Schedule I compounds like psilocybin and psilocin, making treatment more accessible and helping to ease the growing mental health and addiction crisis we are facing today,” he adds.
“We are excited to work with HAVN Life to move forward with our investigational clinical trials including our project in Antigua“, says Revive CEO Michael Frank. He adds, “we are eager to advance the science on botanically-derived ingredients such as psilocin and psilocybin”.
“Mycrodose is very pleased to continue our efforts to progress the use of therapies based on botanically-derived psilocybin products with HAVN Life by expanding the use of psilocybin in research across the United States. Our DEA authorization to legally distribute psilocybin for authorized research purposes helps us facilitate the ease and access of using this Schedule I substance by DEA-licensed Universities, CROs, and other institutions in the United States,” says Chad Conner, Chief Executive Officer, Mycrodose Therapeutics. “We wish Revive Therapeutics and The University of Wisconsin-Madison continued success as they further progress their clinical trials investigation treatments,” he adds.
Revive Therapeutic Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. With its acquisition of Psilocin Pharma Corp. and advancements of its novel oral-thin film delivery system of psychedelic compounds, Revive is working to advance psilocybin-based therapeutics for mental health and abuse disorders.
Mycrodose is one of only a few US-pharmaceutical companies that has been authorized by the United States Drug Enforcement Agency (“DEA”), State of California Attorney General’s Research Advisory Board, and The Food & Drug Administration (“FDA”) to research and develop a total of eight (8) Schedule I and III compounds. In addition, the DEA has granted Mycrodose authorization to import and distribute for resale the controlled substances of psilocybin and psilocin to approved organizations for clinical trials, research and development, and analytical purposes.
HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybe mushrooms.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for investigational research in an effort to define the future of modern medicine. HAVN Life offers a full range of high-quality mushroom and plant extracts that help support immune function and support a healthy lifestyle.
Purchase our plant-based Natural Health Products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. Therapeutics Ltd is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
About Mycrodose Therapeutics Inc.
Mycrodose Therapeutics Inc. is a U.S.-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing DEA Schedule I & III drugs and other compounds to treat cancer related conditions, mental health, and cognitive degenerative diseases. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the purchase order for naturally derived psilocybin from Revive (the “Purchase Order“), the exportation naturally derived GMP psilocybin extract from the Company’s facility in Jamaica into the U.S. through Mycrodose (the “Exportation“) and delivery of the naturally derived GMP psilocybin extract to UW-Madison in order for UW-Madison to conduct research and formulation work (the “Delivery and Use“), Revive’s business, products and future of Revive’s business, Mycrodose’s business, products and future of Mycrodose’s business and the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Purchase Order may not be completed as contemplated, or at all, the risks that the Exportation may not be completed as contemplated, or at all, risks that the Delivery and Use may not be completed as contemplated, or at all, risks that Revive’s products and plan will vary from those stated in this news release and Revive may not be able to carry out its business plans as expected, risks that Mycrodose’s products and plan will vary from those stated in this news release and Mycrodose may not be able to carry out its business plans as expected and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE HAVN Life Sciences Inc.
For further information: Investor Relations: ir@havnlife.com, Media: savi@emergence-creative.com
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) (FSE: 31R) (“Revive”) for use in clinical research studies. The Company previously signed a supply agreement with Revive in October, 2021.
In fulfilling of the purchase order, HAVN Life will export naturally derived GMP psilocybin extract from its facility in Jamaica into the U.S. through its distribution partner, Mycrodose Therapeutics Inc. (“Mycrodose”) for use by the University of Wisconsin-Madison (“UW-Madison”), a Contract Research Organization (“CRO”) for Revive. This shipment of naturally derived psilocybin will allow UW-Madison to conduct research and formulation work to finalize dosing and delivery mechanisms in support of various studies to be sponsored by Revive using an oral-thin and Hydra-gel delivery systems of psychedelics to treat mental health disorders.
“We are so pleased to be able to supply our naturally derived, GMP psilocybin for this potentially ground-breaking research related to addiction disorders,” says HAVN Life CEO Tim Moore. “It is our hope that research like this will help in the push toward the rescheduling of Schedule I compounds like psilocybin and psilocin, making treatment more accessible and helping to ease the growing mental health and addiction crisis we are facing today,” he adds.
“We are excited to work with HAVN Life to move forward with our investigational clinical trials including our project in Antigua”, says Revive CEO Michael Frank. He adds, “we are eager to advance the science on botanically-derived ingredients such as psilocin and psilocybin”.
“Mycrodose is very pleased to continue our efforts to progress the use of therapies based on botanically-derived psilocybin products with HAVN Life by expanding the use of psilocybin in research across the United States. Our DEA authorization to legally distribute psilocybin for authorized research purposes helps us facilitate the ease and access of using this Schedule I substance by DEA-licensed Universities, CROs, and other institutions in the United States,” says Chad Conner, Chief Executive Officer, Mycrodose Therapeutics. “We wish Revive Therapeutics and The University of Wisconsin-Madison continued success as they further progress their clinical trials investigation treatments,” he adds.
Revive Therapeutic Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. With its acquisition of Psilocin Pharma Corp. and advancements of its novel oral-thin film delivery system of psychedelic compounds, Revive is working to advance psilocybin-based therapeutics for mental health and abuse disorders.
Mycrodose is one of only a few US-pharmaceutical companies that has been authorized by the United States Drug Enforcement Agency (“DEA”), State of California Attorney General’s Research Advisory Board, and The Food & Drug Administration (“FDA”) to research and develop a total of eight (8) Schedule I and III compounds. In addition, the DEA has granted Mycrodose authorization to import and distribute for resale the controlled substances of psilocybin and psilocin to approved organizations for clinical trials, research and development, and analytical purposes.
HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybe mushrooms.
###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for investigational research in an effort to define the future of modern medicine. HAVN Life offers a full range of high-quality mushroom and plant extracts that help support immune function and support a healthy lifestyle.
Purchase our plant-based Natural Health Products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
About Mycrodose Therapeutics Inc.
Mycrodose Therapeutics Inc. is a U.S.-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing DEA Schedule I & III drugs and other compounds to treat cancer related conditions, mental health, and cognitive degenerative diseases. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.
Contact:
Investor Relations: ir@havnlife.com
Media: savi@emergence-creative.com
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the purchase order for naturally derived psilocybin from Revive (the “Purchase Order”), the exportation naturally derived GMP psilocybin extract from the Company’s facility in Jamaica into the U.S. through Mycrodose (the “Exportation”) and delivery of the naturally derived GMP psilocybin extract to UW-Madison in order for UW-Madison to conduct research and formulation work (the “Delivery and Use”), Revive’s business, products and future of Revive’s business, Mycrodose’s business, products and future of Mycrodose’s business and the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Purchase Order may not be completed as contemplated, or at all, the risks that the Exportation may not be completed as contemplated, or at all, risks that the Delivery and Use may not be completed as contemplated, or at all, risks that Revive’s products and plan will vary from those stated in this news release and Revive may not be able to carry out its business plans as expected, risks that Mycrodose’s products and plan will vary from those stated in this news release and Mycrodose may not be able to carry out its business plans as expected and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
VANCOUVER, BC / ACCESSWIRE / February 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today the appointment of Dr. Dinesh Bhayana, MD, CCFP (EM), as the Site Medical Director of its recently announced inaugural specialty clinic for interventional psychiatry, located in Mississauga, Ontario. Dr. Bhayana is the Chief Medical Officer of the Centre for Compassionate Care (C3), which offers specialized psychological services including Integrative Ketamine-Enhanced Psychotherapy, served as a Board Member for the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada, and an Emergency and Addiction Medicine physician in several communities within the Greater Toronto Area.
NeonMind and Dr. Bhayana will work closely with medical leaders in NeonMind’s Specialty Clinics Advisory Board to set up the Company’s inaugural NeonMind specialty mental health clinic in Mississauga and leverage their clinical experience to meet regulatory licensing requirements and initiate treatment services this year.
“We are excited to welcome Dr. Bhayana as Site Medical Director of our first specialty clinic. Dr. Bhayana’s extensive training and clinical expertise is particularly well suited for delivering innovative, safe and effective mental health treatments to patients suffering from mood and anxiety disorders,” said Robert Tessarolo, President & CEO of NeonMind.
Dr. Bhayana’s combination of training and experience is complementary for overseeing the administration of innovative mental health treatments. Dr. Bhayana works closely with patients suffering from mental health disorders in his current clinical roles within the emergency department, addiction medicine clinic, and ketamine-enhanced psychotherapy program.
Dr. Bhayana holds various positions including active staff hospital privileges in the departments of Emergency Medicine and Psychiatry. He completed medical school at the Schulich School of Medicine and Dentistry, followed by family medicine and emergency medicine training at the University of Toronto. Dr. Bhayana is certified by the Canadian College of Family Physicians with an Emergency Medicine specialty designation and holds an adjunct Assistant Clinical Professor faculty appointment at McMaster University. He has also completed training in Ketamine Assisted Psychotherapy at the Polaris Insight Center and Ketamine Medical Provider training with the Integrative Psychiatry Institute (IPI).
Dr. Bhayana commented, “I am honored to be appointed as Site Medical Director of NeonMind’s inaugural specialty clinic. Despite the strengths of our Canadian healthcare system, major gaps still remain in access to evidence-based treatments. NeonMind’s team has a strong track record of deploying new medical treatments and a detailed understanding of working in partnership with the healthcare system to address local community needs. I look forward to working with them to ensure access to high quality care that is safe and effective.”
NeonMind’s inaugural specialty mental health clinic is located at 89 Queensway West, Suite 604, Mississauga, Ontario, L5B 2V2. More details will be released closer to the opening of the clinic. For more information related to NeonMind’s specialty clinics, please email medicalinformation@neonmind.com.
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.
NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-based innovative interventional psychiatry treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
SOURCE: NeonMind Biosciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/689960/NeonMind-Appoints-Emergency-and-Addiction-Expert-Dr-Dinesh-Bhayana-as-Site-Medical-Director-of-its-Inaugural-Specialty-Mental-Health-Clinic
Released February 23, 2022
VANCOUVER, BC (February 22, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the official launch of its line of functional mushroom supplements to Canadian consumers. The B.C.-based company is transforming the health and wellness space with formulations made with the highest quality fruiting body mushrooms for whole body and mind optimization.
Through www.optimilife.com, Optimi is now selling high-demand functional mushroom varieties such as Lion’s Mane, http://www.optimelife.com/Reishi, Turkey Tail, Chaga and Cordyceps, which are all known for their significant health benefits and are now being widely adopted by the Western market. Through an eight-hour, eight-step hot water process using highly filtered and naturally mineralized water to break down antinutrients and optimize the fruiting body material, Optimi’s nutraceuticals deliver the maximum benefits from each ingredient.
“As a Canadian company, we are thrilled to bring the significant health benefits of functional mushrooms directly to Canadians and beyond,” says JJ Wilson, Optimi’s Board Chair. “We pride ourselves in offering an industry leading line of supplements made with the highest quality fruiting body mushrooms so Canadians can enjoy all the cognitive and physical benefits of this next level superfood. With operations set to launch at our Princeton facility, we look forward to ultimately growing and cultivating as many of our own functional mushroom strains as possible to vertically-integrate the Company, right here in Canada.”
With an evolving line of six mushroom-based supplements and a vegan protein powder featuring an advanced mushroom complex, Optimi is bringing these health benefits directly to Canadian consumers. Every Optimi product contains nutrient-dense fungi extracted from the whole fruiting body, which provides body and mind benefits such as stress resistance, immune support, energy, stamina, cognition and focus for enhanced physical and mental well-being. Optimi’s science-backed supplements are clean, powerful, and effective for maximum health optimization and increased performance.
Optimi prides itself on supplying the best mushrooms, adhering to cultivation and extraction methods that preserve the integrity and benefits of the raw material. By using clear, simple and easy-to-understand packaging, the brand aims to demystify functional mushrooms and strip away complexity for consumers.
“Our team of researchers, formulators and quality assurance experts at Optimi is second-to-none in the nutraceutical industry,” explains Bill Ciprick, CEO of Optimi Health Corp. “When we couple this expertise with the astute guidance of the Optimi Advisory Board, we can be confident in our ability to be leaders in the therapeutic and functional mushroom market.”
Optimi’s products are now available to Canadian consumers directly at www.optimilife.com and will launch in-store at select retailers later this year.
Bill Ciprick
Chief Executive Officer
Optimi Health Corp.
ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION SEE CONTACT:
Media Contact
Jessica Gauci
Account Manager, Citizen Relations (on behalf of Optimi)
Email: jessica.gauci@citizenrelations.com
Phone: +1 (416) 801-7735
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/
FORWARD‐LOOKING STATEMENTS
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The CSE does not accept responsibility for the adequacy or accuracy of this release.Search
22 FEBRUARY 2022
16 FEBRUARY 2022
7 FEBRUARY 2022
18 JANUARY 2022
5 JANUARY 2022
21 DECEMBER 2021Email
Mississauga facility expected to begin treatment services in the Second Half of 2022
First location selected as part of a nationwide buildout of NeonMind-branded clinics offering interventional psychiatry treatments
Vancouver, B.C. – February 17, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today it has signed an agreement with SRx Health Solutions (“SRx”) to open the Company’s inaugural NeonMind specialty mental health clinic, located at the Queensway Professional Medical Centre in Mississauga, Ontario.
The Mississauga location is the first in NeonMind’s initiative to establish a national network of NeonMind-branded specialty clinics. These clinics will focus on delivering high-demand mental health treatments to underserved areas of Canada. The specialty services to be offered will incorporate innovative, evidence-based interventional psychiatric treatments for a variety of mood and anxiety disorders. The Mississauga clinic is expected to start seeing patients in the second half of 2022.
“Our first NeonMind specialty mental health clinic represents a significant milestone in our multi-pronged strategy to bring the therapeutic benefits of innovative, safe, and effective treatments to patients throughout Canada,” said Robert Tessarolo, President & CEO of NeonMind. “The demand for treatments to address depression and anxiety disorders in Ontario has grown significantly in recent years, yet there remains a supply bottleneck for newer modalities such as ketamine treatment and neurostimulation. Our strategic collaboration with SRx will enable us to purposefully and flexibly enhance access to these treatments for communities in need. We expect to launch additional clinic locations throughout the course of 2022 and beyond, as well as incorporate new treatments, such as psychedelics, as they are approved.”
The Mississauga location enables NeonMind to serve a rapidly growing patient population. Based on NeonMind’s internal estimates, the market for specialized medical services for mental health disorders in Ontario has grown at a CAGR of over 20% from 2017 to 2019. NeonMind’s specific Mississauga location serves an area of Ontario that has seen tremendous demand for specialized mental health services, representing approximately 10% of total demand in Ontario. Demand for specialized services in Mississauga has grown at a CAGR of over 30%, outpacing the overall Ontario market, based on NeonMind’s internal estimates from provincial medical data.
Mr. Brock Clancy, Vice President of Patient Services and Operations at SRx Health Solutions, stated, “The Mississauga location will be a monumental step in enhancing accessibility to cutting-edge treatment solutions. As the fastest growing healthcare services provider in Canada, SRx is committed to making healthcare simple, helping improve the wellness of Canadians, and being a vehicle of innovative change in this space. We are thrilled by our collaboration with NeonMind and look forward to furthering our commitment and helping deliver this type of service to those in need.”
The Queensway Professional Medical Centre is a professional medical building that provides a full range of healthcare services, including a pharmacy and laboratory services, and is equipped with abundant parking facilities and accessibility options. The facility is located on major commuter routes and across from Trillium Health Partners – Mississauga Hospital. NeonMind’s first specialty clinic will provide exceptional, quality services including multiple private, spacious and comforting treatment rooms, as well as a fully-equipped waiting room for patients and caregivers.
NeonMind’s inaugural specialty mental health clinic is located at 89 Queensway West, Suite 604, Mississauga, Ontario, L5B 2V2. More details will be released closer to the opening of the clinic. For more information related to NeonMind’s specialty clinics, please email medicalinformation@neonmind.com.
The Company also announces the resignation of Amber Allen as Vice President of Sales effective January 17, 2022, which was in connection with the divestiture of the NeonMind consumer division assets.
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.
NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-based innovative interventional psychiatry treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com.
About SRx Health Solutions Inc.
SRx Health Solutions is Canada’s leading collaborative network of pharmacists and healthcare practitioners delivering innovative, sustainable, and integrated healthcare solutions. We proudly employ over 400 associates across Canada who support our 30+ pharmacies and 125+ clinics and are dedicated to providing exceptional care to patients. SRx is on a mission to enhance the wellness of Canadians, revolutionize healthcare, and ensure that all Canadians have access to equal, modern health services.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
